How much revenue did Hans Biomed generate this year?
Hans Biomed has achieved a revenue of 125.24 B KRW this year.
Hans Biomed Revenue 2024
Hans Biomed Revenue
125.24 B KRW
Ticker
042520.KQ
ISIN
KR7042520007
In 2024, Hans Biomed's sales reached 125.24 B KRW, a 60.5% difference from the 78.03 B KRW sales recorded in the previous year.
The Hans Biomed Revenue history
| YEAR | REVENUE (undefined KRW) | GROSS MARGIN (%) |
|---|---|---|
| 2025e | 152.01 | 29,69 |
| 2024e | 125.24 | 36,03 |
| 2023 | 78.03 | 57,83 |
| 2022 | 74.46 | 61,35 |
| 2021 | 59.1 | 49,46 |
| 2020 | 80.1 | 53,08 |
| 2019 | 66.99 | 59,93 |
| 2018 | 51.75 | 52,71 |
| 2017 | 39.06 | 46,82 |
| 2016 | 29.05 | 46,18 |
| 2015 | 23.43 | 45,57 |
| 2014 | 21.03 | 45,79 |
| 2013 | 20.07 | 41,39 |
| 2012 | 17.58 | 42,37 |
| 2011 | 15.01 | 37,12 |
| 2010 | 14.63 | 39,58 |
| 2009 | 14.37 | 44,06 |
| 2008 | 12.31 | 49,34 |
| 2007 | 9.57 | 51,06 |
| 2006 | 7.32 | 47,35 |
| 2005 | 5.35 | 46,00 |
| 2004 | 4.71 | 30,43 |
Hans Biomed Revenue, EBIT, Net Income KR7042520007 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Hans Biomed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hans Biomed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hans Biomed’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Hans Biomed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Hans Biomed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Hans Biomed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hans Biomed’s growth potential.
Hans Biomed Revenue, EBIT and net profit per share
| Date | Hans Biomed Revenue | Hans Biomed EBIT | Hans Biomed Net Income |
|---|---|---|---|
| 2025e | 152.01 B undefined | 32.22 B undefined | 29.58 B undefined |
| 2024e | 125.24 B undefined | 20.5 B undefined | 23.78 B undefined |
| 2023 | 78.03 B undefined | -4.15 B undefined | -23.04 B undefined |
| 2022 | 74.46 B undefined | 1.29 B undefined | 6.15 B undefined |
| 2021 | 59.1 B undefined | -19.78 B undefined | -18.29 B undefined |
| 2020 | 80.1 B undefined | -3.41 B undefined | -17.84 B undefined |
| 2019 | 66.99 B undefined | 12.6 B undefined | 9.95 B undefined |
| 2018 | 51.75 B undefined | 10.31 B undefined | 4.02 B undefined |
| 2017 | 39.06 B undefined | 9.46 B undefined | 7.83 B undefined |
| 2016 | 29.05 B undefined | 5.99 B undefined | 4.63 B undefined |
| 2015 | 23.43 B undefined | 5.06 B undefined | 4.91 B undefined |
| 2014 | 21.03 B undefined | 3.91 B undefined | 3.5 B undefined |
| 2013 | 20.07 B undefined | 3.9 B undefined | 3.44 B undefined |
| 2012 | 17.58 B undefined | 3.15 B undefined | 2.52 B undefined |
| 2011 | 15.01 B undefined | 549 M undefined | 778 M undefined |
| 2010 | 14.63 B undefined | 836 M undefined | 1.04 B undefined |
| 2009 | 14.37 B undefined | 2.11 B undefined | 2.1 B undefined |
| 2008 | 12.31 B undefined | 1.98 B undefined | 2.04 B undefined |
| 2007 | 9.57 B undefined | 1.37 B undefined | 1.15 B undefined |
| 2006 | 7.32 B undefined | 1.05 B undefined | 878 M undefined |
| 2005 | 5.35 B undefined | 844 M undefined | 633 M undefined |
| 2004 | 4.71 B undefined | -501 M undefined | -860 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 4.71 B KRW | -501 M KRW | -860 M KRW |
| 2005 | 5.35 B KRW | 844 M KRW | 633 M KRW |
| 2006 | 7.32 B KRW | 1.05 B KRW | 878 M KRW |
| 2007 | 9.57 B KRW | 1.37 B KRW | 1.15 B KRW |
| 2008 | 12.31 B KRW | 1.98 B KRW | 2.04 B KRW |
| 2009 | 14.37 B KRW | 2.11 B KRW | 2.1 B KRW |
| 2010 | 14.63 B KRW | 836 M KRW | 1.04 B KRW |
| 2011 | 15.01 B KRW | 549 M KRW | 778 M KRW |
| 2012 | 17.58 B KRW | 3.15 B KRW | 2.52 B KRW |
| 2013 | 20.07 B KRW | 3.9 B KRW | 3.44 B KRW |
| 2014 | 21.03 B KRW | 3.91 B KRW | 3.5 B KRW |
| 2015 | 23.43 B KRW | 5.06 B KRW | 4.91 B KRW |
| 2016 | 29.05 B KRW | 5.99 B KRW | 4.63 B KRW |
| 2017 | 39.06 B KRW | 9.46 B KRW | 7.83 B KRW |
| 2018 | 51.75 B KRW | 10.31 B KRW | 4.02 B KRW |
| 2019 | 66.99 B KRW | 12.6 B KRW | 9.95 B KRW |
| 2020 | 80.1 B KRW | -3.41 B KRW | -17.84 B KRW |
| 2021 | 59.1 B KRW | -19.78 B KRW | -18.29 B KRW |
| 2022 | 74.46 B KRW | 1.29 B KRW | 6.15 B KRW |
| 2023 | 78.03 B KRW | -4.15 B KRW | -23.04 B KRW |
| 2024e | 125.24 B KRW | 20.5 B KRW | 23.78 B KRW |
| 2025e | 152.01 B KRW | 32.22 B KRW | 29.58 B KRW |
Hans Biomed stock margins KR7042520007 ·
The Hans Biomed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hans Biomed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hans Biomed.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Hans Biomed's sales revenue. A higher gross margin percentage indicates that the Hans Biomed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Hans Biomed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Hans Biomed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hans Biomed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hans Biomed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hans Biomed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Hans Biomed Margin History
| Hans Biomed Gross margin | Hans Biomed Profit margin | Hans Biomed EBIT margin | Hans Biomed Profit margin |
|---|---|---|---|
| 2025e | 57.83 % | 21.2 % | 19.46 % |
| 2024e | 57.83 % | 16.37 % | 18.99 % |
| 2023 | 57.83 % | -5.32 % | -29.53 % |
| 2022 | 61.35 % | 1.74 % | 8.26 % |
| 2021 | 49.46 % | -33.47 % | -30.95 % |
| 2020 | 53.08 % | -4.25 % | -22.27 % |
| 2019 | 59.93 % | 18.8 % | 14.85 % |
| 2018 | 52.71 % | 19.92 % | 7.76 % |
| 2017 | 46.82 % | 24.22 % | 20.04 % |
| 2016 | 46.18 % | 20.62 % | 15.92 % |
| 2015 | 45.57 % | 21.59 % | 20.95 % |
| 2014 | 45.79 % | 18.57 % | 16.63 % |
| 2013 | 41.39 % | 19.45 % | 17.15 % |
| 2012 | 42.37 % | 17.91 % | 14.32 % |
| 2011 | 37.12 % | 3.66 % | 5.18 % |
| 2010 | 39.58 % | 5.72 % | 7.13 % |
| 2009 | 44.06 % | 14.69 % | 14.62 % |
| 2008 | 49.34 % | 16.07 % | 16.6 % |
| 2007 | 51.06 % | 14.28 % | 11.98 % |
| 2006 | 47.35 % | 14.3 % | 11.99 % |
| 2005 | 46 % | 15.76 % | 11.82 % |
| 2004 | 30.43 % | -10.64 % | -18.26 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 30.43 % | -10.64 % | -18.26 % |
| 2005 | 46 % | 15.76 % | 11.82 % |
| 2006 | 47.35 % | 14.3 % | 11.99 % |
| 2007 | 51.06 % | 14.28 % | 11.98 % |
| 2008 | 49.34 % | 16.07 % | 16.6 % |
| 2009 | 44.06 % | 14.69 % | 14.62 % |
| 2010 | 39.58 % | 5.72 % | 7.13 % |
| 2011 | 37.12 % | 3.66 % | 5.18 % |
| 2012 | 42.37 % | 17.91 % | 14.32 % |
| 2013 | 41.39 % | 19.45 % | 17.15 % |
| 2014 | 45.79 % | 18.57 % | 16.63 % |
| 2015 | 45.57 % | 21.59 % | 20.95 % |
| 2016 | 46.18 % | 20.62 % | 15.92 % |
| 2017 | 46.82 % | 24.22 % | 20.04 % |
| 2018 | 52.71 % | 19.92 % | 7.76 % |
| 2019 | 59.93 % | 18.8 % | 14.85 % |
| 2020 | 53.08 % | -4.25 % | -22.27 % |
| 2021 | 49.46 % | -33.47 % | -30.95 % |
| 2022 | 61.35 % | 1.74 % | 8.26 % |
| 2023 | 57.83 % | -5.32 % | -29.53 % |
| 2024e | 57.83 % | 16.37 % | 18.99 % |
| 2025e | 57.83 % | 21.2 % | 19.46 % |
Hans Biomed Aktienanalyse
What does Hans Biomed do?
Hans Biomed ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Hans Biomed's Sales Figures
The sales figures of Hans Biomed originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Hans Biomed’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Hans Biomed's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Hans Biomed’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Hans Biomed stock
How much was the turnover of the company Hans Biomed compared to the previous year?
The revenue of Hans Biomed has increased by 60.5% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Hans Biomed?
The revenue of Hans Biomed is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Hans Biomed measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Hans Biomed so important for investors?
The revenue of Hans Biomed is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Hans Biomed pay?
Over the past 12 months, Hans Biomed paid a dividend of 120 KRW . This corresponds to a dividend yield of about 1.68 %. For the coming 12 months, Hans Biomed is expected to pay a dividend of 365.56 KRW.
What is the dividend yield of Hans Biomed?
The current dividend yield of Hans Biomed is 1.68 %.
When does Hans Biomed pay dividends?
Hans Biomed pays a quarterly dividend. This is distributed in the months of October, October, October, October.
How secure is the dividend of Hans Biomed?
Hans Biomed paid dividends every year for the past 2 years.
What is the dividend of Hans Biomed?
For the upcoming 12 months, dividends amounting to 365.56 KRW are expected. This corresponds to a dividend yield of 5.12 %.
In which sector is Hans Biomed located?
Hans Biomed is assigned to the 'Health' sector.
Wann musste ich die Aktien von Hans Biomed kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Hans Biomed from 1/24/2020 amounting to 120 KRW, you needed to have the stock in your portfolio before the ex-date on 9/27/2019.
When did Hans Biomed pay the last dividend?
The last dividend was paid out on 1/24/2020.
What was the dividend of Hans Biomed in the year 2023?
In the year 2023, Hans Biomed distributed 0 KRW as dividends.
In which currency does Hans Biomed pay out the dividend?
The dividends of Hans Biomed are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Hans Biomed
Our stock analysis for Hans Biomed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hans Biomed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.